Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
作者信息
Paul F, Dörr J, Würfel J, Vogel H-P, Zipp F
出版信息
J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):198-200. doi: 10.1136/jnnp.2006.091033.
Abstract
摘要
相似文献
1
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.米托蒽醌早期诱导的继发进展型多发性硬化症心脏毒性
J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):198-200. doi: 10.1136/jnnp.2006.091033.
2
Mitoxantrone for multiple sclerosis in clinical practice.
Neurology. 2004 Dec 28;63(12 Suppl 6):S25-7. doi: 10.1212/wnl.63.12_suppl_6.s25.
3
The current role of mitoxantrone in the treatment of multiple sclerosis.米托蒽醌在多发性硬化症治疗中的当前作用。
Expert Rev Neurother. 2014 Jun;14(6):607-16. doi: 10.1586/14737175.2014.915742. Epub 2014 May 16.
4
[Mitoxantrone, a new reality].[米托蒽醌，一种新的现实情况]
Rev Neurol. 2003;36(7):698-9.
5
Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.在病情恶化的多发性硬化症患者中，耐受和接受延长的低/延迟米托蒽醌方案。
Eur Neurol. 2011;65(1):40-5. doi: 10.1159/000323013. Epub 2010 Dec 22.
6
Mitoxantrone immunotherapy in multiple sclerosis.米托蒽醌免疫疗法治疗多发性硬化症。
Mult Scler. 1996 Jul;1(6):329-32. doi: 10.1177/135245859600100608.
7
Review of mitoxantrone in the treatment of multiple sclerosis.
Neurology. 2004 Dec 28;63(12 Suppl 6):S19-24. doi: 10.1212/wnl.63.12_suppl_6.s19.
8
The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?米托蒽醌的心脏效应：其在多发性硬化症中的益处是否大于风险？
Expert Opin Drug Saf. 2006 Mar;5(2):265-74. doi: 10.1517/14740338.5.2.265.
9
A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Expert Opin Pharmacother. 2004 Apr;5(4):747-65. doi: 10.1517/14656566.5.4.747.
10
Mitoxantrone (Novantrone) in multiple sclerosis: new insights.米托蒽醌（诺维本）用于治疗多发性硬化症：新见解
Expert Rev Neurother. 2004 Jan;4(1):17-26. doi: 10.1586/14737175.4.1.17.
引用本文的文献
1
A Clinically Relevant Dosage of Mitoxantrone Disrupts the Glutathione and Lipid Metabolic Pathways of the CD-1 Mice Brain: A Metabolomics Study.米托蒽醌的临床相关剂量会破坏 CD-1 小鼠大脑的谷胱甘肽和脂质代谢途径：代谢组学研究。
Int J Mol Sci. 2023 Aug 23;24(17):13126. doi: 10.3390/ijms241713126.
2
Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.通过诱导 MDM2 降解上调 p53：通过在蒽醌核心上引入烷基酮侧链提高效力。
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2370-2381. doi: 10.1080/14756366.2022.2116699.
3
Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice.化疗脑：米托蒽醌诱导成年CD-1小鼠的氧化应激、凋亡及自噬性神经元死亡
Arch Toxicol. 2022 Jun;96(6):1767-1782. doi: 10.1007/s00204-022-03261-x. Epub 2022 Mar 19.
4
Late Cardiotoxicity in MS Patients Treated with Mitoxantrone.接受米托蒽醌治疗的多发性硬化症患者的迟发性心脏毒性
Int J Prev Med. 2019 Dec 10;10:211. doi: 10.4103/ijpvm.IJPVM_477_17. eCollection 2019.
5
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.视神经脊髓炎谱系障碍和髓鞘少突胶质细胞糖蛋白脑病的诊断与治疗
Front Neurol. 2018 Oct 23;9:888. doi: 10.3389/fneur.2018.00888. eCollection 2018.
6
Tobacco mosaic virus delivery of mitoxantrone for cancer therapy.烟草花叶病毒递送米托蒽醌治疗癌症。
Nanoscale. 2018 Aug 30;10(34):16307-16313. doi: 10.1039/c8nr04142c.
7
Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.化疗诱导的心血管功能障碍：生理效应、早期检测——端粒酶对抗线粒体缺陷和氧化应激的作用。
Int J Mol Sci. 2018 Mar 10;19(3):797. doi: 10.3390/ijms19030797.
8
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].[病程修正型多发性硬化症治疗期间的血液参数监测：物质特异性相关性及当前行动建议]
Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1.
9
Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.人诱导多能干细胞衍生心肌细胞中蒽环类药物诱导的心脏毒性的基因组生物标志物鉴定：一种用于安全性评估的体外重复暴露毒性方法。
Arch Toxicol. 2016 Nov;90(11):2763-2777. doi: 10.1007/s00204-015-1623-5. Epub 2015 Nov 4.
10
Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.多发性硬化症中疾病修饰药物相关不良反应的风险缓解策略
CNS Drugs. 2015 Sep;29(9):759-71. doi: 10.1007/s40263-015-0277-4.
本文引用的文献
1
Current perspectives in diastolic dysfunction and diastolic heart failure.舒张功能障碍与舒张性心力衰竭的当前观点
Heart. 2006 May;92(5):712-8. doi: 10.1136/hrt.2005.062950.
2
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.心腔定量推荐：美国超声心动图学会指南与标准委员会及心腔定量写作组的报告，与欧洲心脏病学会下属分支欧洲超声心动图协会联合制定。
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63. doi: 10.1016/j.echo.2005.10.005.
3
Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
Eur Neurol. 2005;54(1):28-33. doi: 10.1159/000087242. Epub 2005 Jul 27.
4
Mitoxantrone treatment of multiple sclerosis: safety considerations.米托蒽醌治疗多发性硬化症：安全性考量
Neurology. 2004 Dec 28;63(12 Suppl 6):S28-32. doi: 10.1212/wnl.63.12_suppl_6.s28.
5
Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods.超声心动图报告左心室收缩功能的可靠性：三种方法的系统评价
Am Heart J. 2003 Sep;146(3):388-97. doi: 10.1016/S0002-8703(03)00248-5.
6
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.米托蒽醌快速引发的继发性进展型多发性硬化症心脏毒性
Mult Scler. 2003 Feb;9(1):59-62. doi: 10.1191/1352458503ms896oa.
7
Mitoxantrone in progressive multiple sclerosis: when and how to treat?
J Neurol Sci. 2003 Feb 15;206(2):203-8. doi: 10.1016/s0022-510x(02)00335-0.
8
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.米托蒽醌治疗进展型多发性硬化症：一项安慰剂对照、双盲、随机、多中心试验。
Lancet. 2002;360(9350):2018-25. doi: 10.1016/S0140-6736(02)12023-X.
9
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.与米托蒽醌（诺维本）治疗多发性硬化症患者相关的心脏不良反应。
Neurology. 2002 Sep 24;59(6):909-13. doi: 10.1212/wnl.59.6.909.
10
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?通过超声心动图、放射性核素心室造影和心血管磁共振成像比较心力衰竭患者的左心室射血分数和容积；它们可以互换吗？
Eur Heart J. 2000 Aug;21(16):1387-96. doi: 10.1053/euhj.2000.2011.
Zotero 插件